Standout Papers

Cannabinoid-based drugs as anti-inflammatory therapeutics 2005 2026 2012 2019 554
  1. Cannabinoid-based drugs as anti-inflammatory therapeutics (2005)
    Thomas Klein Nature reviews. Immunology
  2. Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors (2011)
    Rolf Grempler, Leo Thomas et al. Diabetes Obesity and Metabolism

Immediate Impact

17 by Nobel laureates 19 from Science/Nature 77 standout
Sub-graph 1 of 19

Citing Papers

Mapping the effectiveness and risks of GLP-1 receptor agonists
2025 Standout
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
2022 Standout
13 intermediate papers

Works of Thomas Klein being referenced

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
2020
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
2015
and 4 more

Author Peers

Author Last Decade Papers Cites
Thomas Klein 2740 3455 4757 2940 421 15.3k
Mark G. Currie 1445 4537 1649 739 214 16.8k
Beverly H. Koller 6983 9276 2785 770 202 24.8k
Scott A. Waldman 1427 4954 932 603 342 13.2k
György Haskó 4585 5546 3524 1445 228 20.8k
John A. Wagner 886 5811 912 2037 249 13.6k
Mohan K. Raizada 939 9695 1624 4106 428 21.7k
Kym F. Faull 1496 8588 1248 782 309 16.9k
Irshad H. Chaudry 6591 5122 785 1957 507 22.8k
Manuel Guzmán 645 4681 12226 1593 266 19.7k
Derek W. Gilroy 5141 5003 2397 564 141 16.6k

All Works

Loading papers...

Rankless by CCL
2026